Logo of Racura Oncology (ASX:RAC)Latest Racura Oncology (ASX:RAC) News

Page 2
Page 2 of 5

Racura Oncology Secures $34.3 Million to Fully Fund Three Cancer Trials

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.
Ada Torres
16 June 2026

Healthcare Wrap - Week 23 (1 June -> 5 June) 2026

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.
Logan Eniac
6 June 2026

Racura Oncology Raises $31.2 Million Including $1 Million Institutional Placement

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.
Ada Torres
4 June 2026

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

Racura Oncology Secures $2.3m Underwriting for Expiring Options to Boost Clinical Trials

Racura Oncology has locked in an underwriting agreement covering nearly 1.84 million expiring options, ensuring up to $2.3 million in fresh capital to back its cancer drug development programs.
Ada Torres
28 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Racura Oncology Advances Lung Cancer Trials with Strong Cash Backing

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.
Ada Torres
30 Apr 2026

Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.
Logan Eniac
25 Apr 2026

Racura Oncology Unveils Mechanism Behind MYC Gene Silencing by (E,E)-bisantrene at AACR 2026

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.
Ada Torres
22 Apr 2026

Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.
Logan Eniac
4 Apr 2026

Racura Oncology Recruits First Patient for Pioneering Lung Cancer Trial

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.
Ada Torres
31 Mar 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026